Clinical course of patients with Behçet’s uveitis following discontinuation of infliximab therapy
- 381 Downloads
To investigate the clinical course of Behçet’s uveitis patients following discontinuation of infliximab therapy.
This retrospective chart review study examined Behçet’s disease patients who received infliximab treatment between 2000 and 2012. Medical records of patients whose infliximab treatment was discontinued were reviewed, with special focus on the frequency of uveitis attacks in the period before initiation, during treatment and after cessation of the infliximab therapy. Mean visual acuities were evaluated for each treatment period.
Out of the 43 patients treated with infliximab at our uveitis clinic, ten were discontinued due to adverse events or inefficiency. Data for seven patients followed for more than 12 months before initiation and after cessation of infliximab were analyzed. Frequency of acute uveitis attacks was 7.43 per 12 months before initiation of infliximab, 2.86 during treatment and 0.57 after cessation. A statistically higher frequency of uveitis attacks was observed before initiation of infliximab compared to during (p < 0.05) and after cessation of treatment (p < 0.05). There was no statistical significance observed between the period during treatment and after cessation (p = 0.29). The mean logMAR was 0.79 at baseline, 0.68 during treatment, and 0.88 at 12 months after cessation. These differences were not statistically significant.
A satisfactory clinical course with well-controlled ocular inflammation was found after discontinuation of infliximab therapy in Behçet’s uveitis patients. These results suggest that a safe, pre-planned discontinuation of infliximab therapy can be performed in patients with Behçet’s uveitis.
KeywordsBehçet’s disease Uveitis Infliximab
- 8.Tugal-Tutkun I, Mudun A, Urgancioglu M, Kamali S, Kasapoglu E, Inanc M, et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet’s disease: an open-label trial. Arthritis Rheum. 2005;52:2478–84.PubMedCrossRefGoogle Scholar
- 16.Plank SR, Huang XN, Robertson JE, Rosenbaum JT. Cytokine mRNA in rat tissues after systemic endotoxin treatment. Invest Ophthalmol Vis Sci. 1994;35:924–30.Google Scholar
- 33.Behçet’s disease research committee of Japan. Behçet’s disease: guide to diagnosis of Behçet’s disease. Jpn J Ophthalmol. 1974;18:291–4.Google Scholar
- 35.Quinn MA, Conaghan PG, O’Connor PJ, Karim Z, Greenstein A, Brown A, et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005;52:27–35.PubMedCrossRefGoogle Scholar
- 36.Saleem B, Nizam S, Emery P. Can remission be maintained with or without further drug therapy in rheumatoid arthritis? Clin Exp Rheumatol. 2006; 24(6 Suppl 43): S-33-6.Google Scholar
- 37.Baraliakos X, Listing J, Brandt J, Zink A, Alten R, Burmester G, et al. Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Res Ther. 2005;7:R439–44.PubMedCentralPubMedCrossRefGoogle Scholar